You are using an outdated browser and your browsing experience will not be optimal. Please update to the latest version of Microsoft Edge, Google Chrome or Mozilla Firefox. Install Microsoft Edge

April 28, 2011

Proceed with Caution on Compulsory Licensing

Informed Counsel

Developing countries that seek to implement compulsory licensing face a crucial dilemma—between greater innovation and greater access. As long as inadequate and inequitable mechanisms to stimulate health research and development (R&D) exist, developing countries should be extremely cautious in undertaking measures, such as compulsory licensing, that could be detrimental to the development of new drugs.

RELATED INSIGHTS​